Dr. Schlumbrecht on Remaining Challenges in Uterine Leiomyosarcoma

Partner | Cancer Centers | <b>Sylvester Comprehensive Cancer Center</b>

Matthew P. Schlumbrecht, MD, discusses remaining challenges in uterine leiomyosarcoma.

Matthew P. Schlumbrecht, MD, associate professor and co-director of Cancer Prevention and Control, Division of Gynecologic Oncology, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses remaining challenges in uterine leiomyosarcoma.

Historically, uterine leiomyosarcoma has been a difficult tumor to treat, explains Schlumbrecht. Studies have not definitively shown that up front chemotherapy is effective. Additionally, a limited number of chemotherapy and targeted therapy has shown activity in the recurrent setting.

As such, the prognosis for women with this disease remains poor, says Schlumbrecht.

Going forward, identifying predictive biomarkers and underlying genetic mutations may help the field understand which patients are more likely to respond to treatment, concludes Schlumbrecht.